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Abstract
Background: Theaflavins including theaflavin (TF), theaflavin-3-gallate (TF3G), theaflavin-39-gallate (TF39G), and theaflavin-
3,39-digallate (TFDG), are the most important bioactive polyphenols in black tea. Because of their poor systemic
bioavailability, it is still unclear how these compounds can exert their biological functions. The objective of this study is to
identify the microbial metabolites of theaflavins in mice and in humans.
Methods and Findings: In the present study, we gavaged specific pathogen free (SPF) mice and germ free (GF) mice with
200 mg/kg TFDG and identified TF, TF3G, TF39G, and gallic acid as the major fecal metabolites of TFDG in SPF mice. These
metabolites were absent in TFDG- gavaged GF mice. The microbial bioconversion of TFDG, TF3G, and TF39G was also
investigated in vitro using fecal slurries collected from three healthy human subjects. Our results indicate that TFDG is
metabolized to TF, TF3G, TF39G, gallic acid, and pyrogallol by human microbiota. Moreover, both TF3G and TF39G are
metabolized to TF, gallic acid, and pyrogallol by human microbiota. Importantly, we observed interindividual differences on
the metabolism rate of gallic acid to pyrogallol among the three human subjects. In addition, we demonstrated that
Lactobacillus plantarum 299v and Bacillus subtilis have the capacity to metabolize TFDG.
Conclusions: The microbiota is important for the metabolism of theaflavins in both mice and humans. The in vivo functional
impact of microbiota-generated theaflavins-derived metabolites is worthwhile of further study.
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Introduction
Tea is one of the most widely consumed beverages in the world,
with black tea accounting for 78% of the production. Consump-
tion of tea has been associated with many health benefits including
the prevention of cancer and heart disease [1–3], a phenomenon
mostly attributed to the presence of polyphenolic compounds.
Theaflavins including theaflavin (TF), theaflavin-3-gallate (TF3G),
theaflavin-39-gallate (TF39G), and theaflavin-3,39-digallate
(TFDG) (Figure 1) are the major bioactive polyphenols present
in black tea. They are formed from co-oxidation of selected pairs
of catechins in tea leaves during fermentation [4].
Recently, theaflavins have received extensive attention due to
their antioxidative, anti-inflammatory, and anti-tumor activities
[5,6]. However, it has been reported that theaflavins have poor
systemic bioavailability. Very limited amounts of TFDG
(,1 nmol/g tissue) were detected in tissue samples collected from
mice treated with decaffeinated black tea (50 mg/g diet) for two
weeks [7]. The Cmax of theaflavin in human plasma and urine
was only 1 ng/mL and 4.2 ng/mL, respectively, following
consumption of 700 mg of a pure mixture of theaflavins; which
is equivalent to about 30 cups of black tea [8]. Neither theaflavin
mono- nor di-gallates were detectable in this study. It has become
clear that the bioavailability of theaflavins generally is far too low
to explain direct bioactivities.
In general, large molecular weight polyphenols (eg, M.W. .500)
are thought to be poorly absorbed [9]. A major portion of
unabsorbed polyphenols will reach the large intestine where they
will be metabolized by the gut microbiota to a wide range of lower
molecular weight metabolites, which are generally better absorbed
by the host [10]. We have reported TF, TF3G, TF39G, and gallic
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acid (GA) as the major fecal metabolites of TFDG in mice and
hypothesized that these compounds are the microbial metabolites
of TFDG [11]. However, definitive involvement of bacteria in the
metabolism of TFDG remains to be established.
Culture models of human colonic microbiota that simulate
microbial processes in the large intestine have been widely used to
investigate the microbial metabolism of dietary polyphenols [12–
14]. The complexity of in vitro gut models is diverse, ranging from
simple fecal batch fermentation to advanced continuous models,
such as the Reading model, the Simulator of the Human Intestinal
Microbial Ecosystem (SHIME), and the TNO Intestinal Model 2
(TIM2) [14]. Compared to more sophisticated, but time consum-
ing in vitro gut models, fecal batch incubations provide a simple
mean to assess multiple experimental conditions by using fecal
samples from different subjects [15]. In addition, this approach
can help to shed light on the inter-individual variations on the
metabolism of polyphenols due to differences in microbial
community composition of different human subjects [14]. Another
powerful approach is the utilization of germ-free mice where
microbial status on a given rodent is amenable to experimental
manipulation, hence providing a unique opportunity to address
the role of bacteria in a specific biological process [16,17].
In the present study, we investigated the metabolism of TFDG
using specific pathogen free (SPF) and germ-free (GF) mice, to
determine the functional role of bacteria in the metabolism of
TFDG. We also used specific bacteria to investigate the
metabolism of TFDG. Furthermore, we utilized in vitro batch
fermentations using fecal samples from human volunteers to define
theaflavins metabolism. We report that the microbiota is essential
for the metabolisms of TFDG, TF3G, and TF39G.
Results
Metabolism of TFDG in SPF Mice and GF Mice
We have identified TF, TF3G, TF39G, and GA as the major
fecal metabolites of TFDG in mice and hypothesized that these
compounds are the product of microbial enzymatic activities [11].
To test this hypothesis, fecal samples were collected from SPF and
GF mice treated with 200 mg/kg TFDG via oral gavage and
analyzed by HPLC coupled with electrochemical detector (ECD)
(Figure 2). Compared with the samples collected from control
mice, 4 major metabolites (M22M5) were observed in fecal
samples collected from TFDG treated SPF mice (Figures 2A). The
four metabolites showed the same retention times as those of the
Figure 1. Structures of TFDG, TF3G, TF39G, TF, GA, and PG and the potential biotransformation pathways of TFDG, TF3G, TF39G,
and GA by human microbiota. TFDG: theaflavin 3,39-digallate; TF3G: theaflavin 3-gallate; TF39G: theaflavin 39-gallate; TF: theaflavin; GA: gallic acid;
and PG: pyrogallol.
doi:10.1371/journal.pone.0051001.g001
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authentic standards of GA, TF, TF3G, and TF39G (Figure 2A).
The structures of the four metabolites were confirmed by LC/MS
analysis (data not shown). Whereas, none of those metabolites
were detected in fecal samples collected from TFDG treated GF
mice (Figure 2B), indicating that those metabolites are indeed the
microbial metabolites of TFDG in mice.
Metabolism of Theaflavins by Human Microbiota
To investigate the metabolism of theaflavins by human
microbiota, TFDG, TF3G and TF39G were incubated with fecal
slurries collected from three healthy subjects. Samples were
collected as a function of time (0, 6, 12, 24, 48, and 72 h) and
analyzed by HPLC-ECD and LC/MS for characterization of the
derived microbial metabolites. Figure 3 shows the representative
HPLC chromatograms of TFDG incubated with human fecal
slurries. TFDG was degraded progressively with time increasing.
GA, TF, TF3G and TF39G (M2–M5) were identified as the
metabolites of TFDG by comparing their retention time and
tandem mass data with those of the authentic standards (data not
shown). In addition, a new peak (M1, RT: 6.5 min) appeared at
the time point of 12 h in all three samples. This new metabolite
had a molecular weight of 126 as determined by the mass ion at
m/z 125 [M2H]2, which is the same as that of pyrogallol (PG)
(m/z 125 in negative mode) (data not shown). Further tandem
mass analysis indicated that the mass fragments of M1 was almost
identical to those of the authentic PG (Figure 4D), suggesting that
M1 is PG. To further confirm this, we incubated GA with human
fecal slurries and analyzed those samples using HPLC-ECD
(Figures 4A–4C). Our results clearly indicated that PG is the
microbial metabolite of GA (Figure 1). Moreover, interindividual
differences were observed on the metabolism rate of GA to PG
among the three human subjects (Figures 4A24C). GA was almost
completely degraded to PG after 48 h incubation with fecal
slurries collected from subject C and very little GA was degraded
to PG even after 72 h incubation with fecal slurries collected from
subject B (Figures 4A24C). This phenomenon was also observed
in the incubation of TFDG with fecal slurries (Figure 3).
We hypothesized that TFDG can be metabolized to TF3G and
TF39G and then both TF3G and TF39G can be further degraded
to TF by gut microbiota. To test this hypothesis, TF3G and
TF39G were incubated with human fecal slurries for up to 72 h.
The samples were analyzed by HPLC-ECD as well as LC/MS.
Figures 5 and 6 showed that both TF3G and TF39G could be
metabolized to TF and GA, and GA was further metabolized to
PG by gut microbiota.
Effects of Specific Bacteria on the Metabolism of TFDG
It has been reported that Lactobacillus plantarum exhibited galloyl-
esterase and decarboxylase activities which allowed hydrolysis of
the grape seed polyphenols and leads to the formation of gallic
acid and pyrogallol, respectively [18]. In addition, different kinds
of esterases from Bacillus subtilis have been isolated and demon-
Figure 2. HPLC-ECD chromatograms of fecal samples collected from TFDG (treated, 200 mg/kg, oral gavage) or DMSO (control)
treated special pathogen free (SPF) mice (A) and germ-free (GF) mice (B). TFDG: theaflavin 3,39-digallate.
doi:10.1371/journal.pone.0051001.g002
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strated to hydrolyze various esters [19–21]. Therefore, we selected
these two bacteria to assess their impact on TFDG metabolism.
Lactobacillus plantarum 299v and Bacillus subtilis were incubated with
TFDG and samples were collected as a function of time (up to
72 h) and analyzed by HPLC-ECD and LC/MS. Figure 7 shows
the representative HPLC chromatograms of TFDG incubated
with Lactobacillus plantarum 299v (Figure 7A) and Bacillus subtilis
(Figure 7B). TFDG was degraded progressively with time
increasing. PG, GA, TF, TF3G and TF39G (M1–M5) were
identified as the metabolites of TFDG by comparing their
retention time and tandem mass data with those of the authentic
standards (data not shown).
Discussion
Increasing evidence has shown that theaflavins have antiox-
idative, anti-inflammatory, and antitumor activities [5,6]. Studies
have also reported that theaflavins have limited bioavailability
with extremely low or no circulating levels in plasma [4,7,8].
Therefore, a critical question is whether theaflavins-mediated
beneficial effects in peripheral tissues are accomplished by
theaflavin-derived metabolites. In general, the unabsorbed poly-
phenols will reach the large intestine where they will be
metabolized by the gut microbiota to lower molecular weight
metabolites [22]. We previously identified TF, TF3G, TF39G, and
GA as the major fecal metabolites of TFDG in C57BL/6J mice
[11]. Using GF mice, we observed the absence of TFDG-derived
metabolites compared to SPF mice. This finding definitely
established the critical role of the microbiota enzymatic activities
in generating TFDG-derived metabolites. These compounds are
the microbial metabolites of TFDG through the cleavage of its
galloyl groups.
Human colon plays host to a highly complex microbial
ecosystem, at concentrations of 1012 microorganisms per gram
of gut content [14]. Using in vitro fecal batch fermentation, we
found that TF, TF3G, TF39G, and GA are also the microbial
metabolites of TFDG in human. In addition, we also identified PG
as the metabolite of TFDG, TF3G, TF39G, and GA by human
microbiota. Furthermore, we directly demonstrated that pure
bacterial strains (Lactobacillus plantarum 299v and Bacillus subtilis) are
capable to metabolize TFDG into PG, GA, TF, TF3G and
TF39G.
Both L. plantarum and B. subtilis can be considered as gut
commensals. Several studies have shown that L. plantarum,
although commonly referred as a probiotic, could colonize the
human intestine [23–26]. Johansson and co-workers have isolated
this bacterium from jejunal and rectal biopsies 11 days after the
original administration in 11 of 13 individuals [24]. It has been
suggested that the human gastrointestinal tract can adapt to
harbor this species as part of the normal microbiota after
continuous exposure to it [23]. B. subtilis has been isolated from
human ileum biopsies as well as from fecal samples [27]. Studies
have also shown that L. plantarum has the capacity to metabolize
the galloylated polyphenols from grape seeds to gallic acid and
pyrogallol [18], and B. subtilis has a large spectrum of esterases that
hydrolyze various esters [19–21]. However, it is still unknown
Figure 3. HPLC-ECD chromatograms of microbial metabolites of TFDG after incubation with human fecal bacteria (A–C). A, B and C
represent the three human volunteers, respectively. TFDG: theaflavin 3,39-digallate.
doi:10.1371/journal.pone.0051001.g003
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whether these enzymes can metabolize theaflavin esters. Our study
demonstrates, for the first time, the capacity of L. plantarum and
B. subtilis to metabolize theaflavin mono- and di-gallate to TF,
gallic acid and pyrogallol.
Our results on the microbial metabolism of theaflavin esters
(TFDG, TF3G, and TF39G) are consistent with previous findings
that microbial enzymes cleave the gallate group of (–)-epigalloca-
techin 3-O-gallate (EGCG) and (–)-epicatechin 3-O-gallate (ECG)
[13,28]. PG was reported as the major metabolite detected in both
plasma and urine of rats fed ECG indicating that PG can be
absorbed from the colon and then enters into the circulating
system [29]. Both 2-O-sulfate-pyrogallol and 4-O-methyl-gallic
acid were identified as the markers for black tea intake in human
[30,31], which further demonstrated that lower molecular weight
microbial metabolites can be absorbed by the host.
Unbiased metagenomics sequencing has revealed that the
human distal intestinal microbiota comprises two predominant
phyla, the Firmicutes and Bacteroidetes, with lesser contributions
from Proteobacteria and Actinobacteria, and minor contributions
from Fusobacteria, Verrucomicrobia and Cyanobacteria [32,33].
Remarkably, at the phylum level the murine microbiota is very
similar to the one observed in human [34]. Our study shows a
similar profile of microbial metabolites of TFDG between mice
and human, suggesting that functional studies on these metabolites
could be performed in mice. Nevertheless, our human fecal batch
fermentation experiment has identified PG as metabolite of
TFDG, TF3G, TF39G, and GA suggesting that the human gut
microbiota has a slightly different capacity to metabolize
theaflavins as compared to the murine microbiota. This would
be consistent with the unique profile of human microbiota
compared to the murine one at the genus levels [34]. Future
experiments using human fecal transplantation in mice are
currently underway to better define the role of human biota in
TFDG metabolism.
Another important finding is the interindividual variation on the
metabolism rate of GA to PG between human donors. The
interindividual variability on the biotransformation of polyphenols
into their microbial metabolites has been reported and recognized
as an essential part of personalized nutrition approaches
[14,22,35]. For example, only 25–30% of the adult population
of Western countries and 50–60% of the adults from Japan,
Korea, or China produce equol, the microbial metabolite of soy
isoflavone daidzein [35]. It has been reported that isoflavone
treatment in equol producer differentially affects gene expression
as compared with nonproducers and a stronger effect on some
putative estrogen-responsive genes was observed in equol produc-
Figure 4. HPLC-ECD chromatograms of microbial metabolites of GA after incubation with human fecal bacteria (A–C); and MS/MS
(negative ion) spectra of M1 and authentic PG (D). A, B and C represent the three human volunteers, respectively. GA: gallic acid; and PG:
pyrogallol.
doi:10.1371/journal.pone.0051001.g004
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ers than in nonproducers [36]. In our study, subject B can hardly
metabolize GA to PG, whereas, subject C almost completely
metabolizes GA to PG within 48 h incubation. Subject A has
moderate activity in terms of metabolizing GA to PG. This
suggests that microbial composition may impact on the ability of a
given individual to generate theaflavins-derived metabolites. Next-
generation sequencing on fecal material would help identify
bacterial community associated with theaflavins-derived metabo-
lites. These experiments may prove important in defining the
human population better suited to generate theaflavins-derived
metabolites. This population may include better responders of
theaflavins-mediated beneficial effects.
Numerous studies have demonstrated that gut microbiota can
cleave the C-ring of tea catechins to generate several lower
molecular weight phenolic acids as well as ring-fission metabolites,
such as 4-hydroxylphenylacetic acid, 3-(3-hydroxyphenyl)-propio-
nic acid, 5-(39,49-dihydroxyphenyl)-c-valerolactone, and 5-
(39,49,59-trihydroxyphenyl)-c-valerolactone [4,22,37]. With the
unique benzotropolone structure, it is unlikely that theaflavins
can be metabolized to similar simple phenolic compounds as
catechins do. We did observe several metabolites of TF from fecal
samples collected from TF treated mice through oral gavage
(200 mg/kg) (data not shown). However, we were unable to
identify any benzotropolone-derived metabolites of TF by
searching potential degradation metabolites using LC/MS. It is
worthwhile to investigate how the benzotropolone structure of
theaflavins is metabolized by gut microbiota in order to gain a full
picture on the microbial metabolism of theaflavins.
The in vivo functional impact of microbiota-generated thea-
flavins-derived metabolites is unclear. However, multiple studies
have revealed that both GA and PG play an important role in the
inhibition of cancer. It is reported that GA induced apoptosis in
A375.S2 human melanoma cells and suppressed lipopolysaccha-
ride-induced nuclear factor-kB signaling by preventing ReIA
acetylation in A-549 lung cancer cells [38,39]. Several laboratory
animal studies have shown that GA can prevent cancer in different
organs including colon, prostate and lung [40–45]. In addition,
PG has been reported to inhibit the growth of human lung cancer
Calu-6 cells via multi pathways [46–49]. Han et al. found PG
inhibited the growth of human pulmonary adenocarcinoma A549
cells by arresting cell cycle and triggering apoptosis [50].
Furthermore, Yang et al. reported that PG induced G2-M arrest
in human lung cancer cells and inhibited tumor growth in a
xenograft nude mouse model [51]. However, the impact of these
microbial-derived metabolites on cancer prevention observed from
theaflavins is currently unknown. Moreover, the functional impact
of various member of the microbiota on metabolite generation
remains to be defined.
Materials and Methods
Chemicals and Reagents
TF, TF3G, TF39G, and TFDG were prepared previously in our
laboratory [52]. Gallic acid, pyrogallol and Tween 80 were
purchased from Sigma-Aldrich (St. Louis, MO). Peptone was
obtained from VWR Scientific (South Plainfield, NJ). HPLC-
Figure 5. HPLC-ECD chromatograms of microbial metabolites of TF3G after incubation with human fecal bacteria (A–C). A, B and C
represent the three human volunteers, respectively. TF3G: theaflavin 3-digallate.
doi:10.1371/journal.pone.0051001.g005
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grade and LC/MS-grade solvents and other reagents were
purchased from Thermo Fisher Scientific (Pittsburgh, PA).
Treatment of Mice and Feces Collection
Experiments with mice were carried out according to a protocol
approved by the Institutional animal Care and Use Committee of
the University of North Carolina at Chapel Hill. Eight week-old
129 SvEv mice were bred and housed in the Gnotobiotic Animal
Facility at the University of North Carolina at Chapel Hill. TFDG
was dissolved in dimethyl sulfoxide (DMSO) and then filtered
sterilized using 0.22 mm filters (Fisher, Pittsburgh, PA). To insure
sterility, aliquots of TFDG were placed on heart-brain infusion
agar (Becton Dickinson, Franklin Lakes, NJ) and incubated in
aerobic or anaerobic conditions for 24 h. After fasting for 12
hours, TFDG (200 mg/kg) was administered to germ-free (GF)
mice by oral gavage. All feces were collected from the cage within
24 h after administration of DMSO (control group, n = 5) or
TFDG (treated group, n = 5). Concurrently, age-matched 129
SvEv mice raised in specific pathogen free (SPF) (conventional-
ized-raised) conditions were administered TFDG (200 mg/kg;
n = 5/group) by oral gavage. Feces were collected as described
above. All samples were stored at 280uC before analysis.
Fecal Sample Preparation
For acquisition of the metabolic profile, eight pieces of each
fecal sample (control and treated) were chosen and put into 2 mL
tubes. Each set was weighted (control: 78 mg and treated: 81 mg)
and 1.2 mL of MeOH/H2O (50/50)+0.1% acetic acid was added
to each sample. Samples were sonicated for 90 minutes, and then
centrifuged at 17000 RPM for 10 minutes. The supernatants
(650 mL) were removed from the centrifuged samples and
transferred to LC/MS vials for analysis.
Human Fecal Slurry Preparation and in vitro
Fermentation
The Institutional Review Board approved the protocol for
human experimentation through the Protection of Human
Subjects in Research at North Carolina Agricultural and
Technical State University (Greensboro, NC). Three healthy male
volunteers (30–39 years old, weighing 60–80 kg, nonsmokers)
participated in the study. They had not taken antibiotics for at
least 6 months prior to the study, and had avoided polyphenol-rich
foods for at least 48 h before fecal collection. Fecal samples were
collected and transferred immediately to anaerobic condition to be
processed within 2 h. Under aseptic conditions, 50 g of fresh
collected fecal sample was homogenized under anaerobic condi-
tions with 100 mL 0.05% peptone water in a sterilized stomacher
bag using a Seward stomacher (Model: 400 circulator) for 3 min at
200 rpm. The mixture was briefly centrifuged (2–3 min at
3000 rpm) to remove particulate materials. The supernatant (fecal
slurry) was mixed with 35% pre-sterile glycerol, divided into
15 mL sterilized tubes, and stored at 280uC for later use.
The in vitro fermentation experiment was performed under
conditions described in Gross et al. with some modifications [13].
Figure 6. HPLC-ECD chromatograms of microbial metabolites of TF39G after incubation with human fecal bacteria (A–C). A, B and C
represent the three human volunteers, respectively. TF39G: theaflavin 39-gallate.
doi:10.1371/journal.pone.0051001.g006
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Fermentation basal medium was prepared by mixing 1000 mL of
distilled water with 4 mL of Tween 80 and 2 g of peptone and
autoclaved at 121uC for 15 minutes then stored in refrigerator for
later use. TFDG, TF3G, TF39G, and GA were dissolved in water/
ethanol (1:1) to obtain a concentration of 10 mg/mL. Then,
100 mL of the dissolved sample was added to 8.9 mL of
fermentation medium and 1 mL of fecal slurry. The mixture
was vigorously mixed and divided into six sets of samples
(,1.7 mL each) to represent 0, 6, 12, 24, 48, and 72 h time
points. Samples were incubated at 37uC under anaerobic
conditions and harvested according to the designated time points.
Once harvested, each sample was centrifuged at 10,000 rpm for 8
minutes and 20 mL of the supernatant was picked up and mixed
with 170 mL 99.9% methanol and 10 mL 2% acetic acid for HPLC
analysis.
In vitro Fermentation of TFDG by Different Bacterial
Strains
Two bacterial strains (Lactobacillus plantarum 299v and Bacillus
subtilis) were used in this study. Lactobacillus plantarum 299v was
kindly donated by the laboratory of Dr. R. Balfour Sartor of
University of North Carolina at Chapel Hill. Bacillus subtilis was
isolated from a human fecal sample and currently is part of the
bacterial strain culture collection in the Food Microbiology and
Biotechnology Laboratory at North Carolina A&T State Univer-
sity. These strains were stored at 280uC and were activated in
MRS (deMan Ragusa Sharp) (Neogen, Lansing, MI USA) broth
by transferring 100 mL of the stored culture to 5 mL MRS broth
and incubated under anaerobic conditions at 37uC for 24 h.
Activated strains were then stored at 4uC. Prior to each
experimental use, individual bacterial strain was streaked on
MRS agar, incubated under anaerobic conditions at 37uC for
24 h. A single colony was transferred to 10 mL MRS broth, and
incubated under anaerobic conditions at 37uC for 18 h.
Basal medium was prepared by mixing 200 mL of distilled
water with peptone (0.5 g), yeast extract (0.5 g), Tween 80
(0.2 ml), glucose (5 g), L-cysteine (0.2 g), ascorbic acid (0.15 g),
sodium bicarbonate (NaHCO3, 2 g), disodium phosphate
(Na2HPO4, 0.5 g), sodium acetate (CH3COONa, 2 g), magne-
sium sulfate (MgSO4?7H2O, 0.04 g and MnSO4?5H2O, 0.02 g),
and ammonium acetate (CH3COONH4, 0.5 g) and autoclaved at
121uC for 15 minutes. TFDG was dissolved in water/ethanol (1:1)
to obtain a concentration of 10 mg/mL and then, 100 mL of
dissolved sample was added to 9.0 mL of sterilized basal medium
and inoculated individually with 1 mL of active culture. Samples
were then divided into seven sets (,1.7 mL each) to represent 0, 6,
12, 24, 36, 48, and 72 h time points. Samples were incubated at
37uC under anaerobic conditions and harvested according to the
Figure 7. HPLC-ECD chromatograms of microbial metabolites of TFDG after incubation with Lactobacillus plantarum 299v (A) and
Bacillus subtilis (B). TFDG: theaflavin 3,39-digallate.
doi:10.1371/journal.pone.0051001.g007
Microbial Metabolites of Theaflavins
PLOS ONE | www.plosone.org 8 December 2012 | Volume 7 | Issue 12 | e51001
designated time points. Once harvested, each sample was
centrifuged at 10,000 rpm for 8 minutes and 20 mL of the
supernatant was mixed with 170 mL 99.9% methanol and 10 mL
2% acetic acid for HPLC analysis.
HPLC Analysis
An HPLC-ECD (ESA, Chelmsford, MA) consisting of an ESA
model 584 HPLC pump, an ESA model 542 autosampler, an ESA
organizer, and an ESA electrochemical detector (ECD) coupled
with two ESA model 6210 four sensor cells was used for analyzing
mouse fecal samples as well as the samples collected from the
in vitro fermentation experiments. A Gemini C18 column
(150 mm64.6 mm, 5 mm; Phenomenex, Torrance, CA) was used
for chromatographic analysis at a flow rate of 1.0 mL/min. The
mobile phases consisted of solvent A (30 mM sodium phosphate
buffer containing 1.75% acetonitrile and 0.125% tetrahydrofuran,
pH 3.35) and solvent B (15 mM sodium phosphate buffer
containing 58.5% acetonitrile and 12.5% tetrahydrofuran,
pH 3.45). The gradient elution had the following profile: 0% B
from 0 to 10 min; 0–30% B from 10 to 20 min; 30–40% B from
20 to 35 min; 40–50% B from 35 to 50 min; 50–100% B from 50
to 55 min; 100% B from 55 to 59 min; and then 0%B from 59.1 to
64 min. The cells were then cleaned at a potential of 1000 mV for
1 min. The injection volume of the sample was 10 mL. The eluent
was monitored by the Coulochem electrode array system (CEAS)
with potential settings at 50, 200, 300, 400, 500, 600, and
700 mV. Data for Figures 2, 3, 4, 5, 6 was from the channel set at
50 mV of the CEAS.
LC/ESI-MS Method
LC/MS analysis was carried out with a Thermo-Finnigan
Spectra System which consisted of an Accela high-speed pump, an
Accela refrigerated autosampler, and an LTQ Velos ion trap mass
detector (Thermo Electron, San Jose, CA) incorporated with
heated electrospray ionization (H-ESI) interfaces. A Gemini C18
column (5062.0 mm i.d., 3 mm; Phenomenex, Torrance, CA) was
used for separation of theaflavins and their potential metabolites at
a flow rate of 0.2 mL/min. The column was eluted with 100%
solvent A (H2O with 0.1% formic acid) for 3 min, followed by
linear increases in B (acetonitrile with 0.1% formic acid) to 70%
from 3 to 48 min and to 100% B from 48 to 49 min, and then
with 100% B from 49 to 54 min. The column was re-equilibrated
with 100% A for 5 min. A Gemini C18 column (15063.0 mm i.d.,
5 mm; Phenomenex, Torrance, CA) was used for separation of
phenolic acids and their potential metabolites at a flow rate of
0.3 mL/min. The column was eluted with 100% solvent A (H2O
with 0.1% formic acid) for 5 min, followed by linear increases in B
(acetonitrile with 0.1% formic acid) to 100% from 5 to 15 min,
and then with 100% B from 15 to 20 min. The column was re-
equilibrated with 100% A for 5 min. The LC eluent was
introduced into the H-ESI interface. The negative ion polarity
mode was set for the H-ESI source with the voltage on the H-ESI
interface maintained at approximately 4 kV. Nitrogen gas was
used as the sheath gas and auxiliary gas. To detect the theaflavins
and their metabolites, optimized source parameters, including ESI
capillary temperature (300uC), capillary voltage (–50 V), ion spray
voltage (3.6 kV), sheath gas flow rate (30 units), auxiliary gas flow
rate (5 units), and tube lens (–120 V), were tuned using authentic
TFDG. To detect the phenolic acids and their metabolites,
optimized source parameters were tuned using authentic gallic
acid. These parameters include ESI capillary temperature (300uC),
capillary voltage (–50 V), ion spray voltage (3.6 kV), sheath gas
flow rate (35 units), auxiliary gas flow rate (15 units), and tube lens
(–60 V). The collision-induced dissociation (CID) for H-ESI was
conducted with an isolation width of 2 Da and normalized
collision energy of 35 for MS2 and MS3. Default automated gain
control target ion values were used for MS, MS2, and MS3
analyses. The mass range was from 50 to 1000 m/z for detection
TFs and their metabolites, from 50 to 400 m/z for detection
phenolic acids and their metabolites. The mass resolution was 0.6
amu FWHM. Data acquisition was performed with Xcalibur
version 2.1.0 (Thermo Electron, San Jose, CA).
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